Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck Declares Record Date and Dividend for the Organon & Co. Spinoff

Business Wire May 7, 2021

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program

Business Wire May 6, 2021

Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma

Business Wire May 6, 2021

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Business Wire May 5, 2021

Merck Hosts Organon Investor Day Outlining New Company's Vision, Focus and Business Model for Sustained Growth

Business Wire May 3, 2021

Merck Announces First-Quarter 2021 Financial Results

Business Wire April 29, 2021

Merck to Hold Investor Briefing Featuring Organon on May 3

Business Wire April 27, 2021

Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19

Business Wire April 27, 2021

Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025

Business Wire April 26, 2021

Merck to Discontinue Development of MK-7110 for COVID-19

Business Wire April 15, 2021

Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19

Business Wire April 15, 2021

Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week

Business Wire April 14, 2021

Organon Announces Pricing of Senior Notes Offering

Business Wire April 8, 2021

Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery

Business Wire April 8, 2021

Organon Announces Proposed Senior Notes Offering

Business Wire April 6, 2021

Merck Completes Acquisition of Pandion Therapeutics

Business Wire April 1, 2021

Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon

Business Wire March 30, 2021

Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Business Wire March 30, 2021

Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Business Wire March 29, 2021

Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29

Business Wire March 29, 2021